Blog
Immunotherapy Update: What We’ve Learned
Immunotherapy has been called one of the most significant advances in cancer in decades. While this approach may work in some cancers, it is unclear
September 11, 2018
1 Comment
Immunotherapy has been called one of the most significant advances in cancer in decades. While this approach may work in some cancers, it is unclear
We are saddened to hear of the passing of Aretha Franklin, the Queen of Soul, who died of a pancreatic neuroendocrine tumor (pNET). She was
We are pleased to announce a $100,000 grant from the Karpus Family Foundation, Rochester, NY. The grant will help us discover insights into the life cycle
New Potential NET Treatment under Investigation It is hard for doctors to know which patients will respond to which therapies. New approaches in personalized medicine
David Van Bibber calls his neuroendocrine cancer diagnosis a blessing in disguise.it. Since his 2010 diagnosis at the age of 32, David’s priorities and perspectives have changed. As a result, he has invested more deeply in his health, his family, and his community. Now he is reaping the rewards of that investment and finding daily joy in his life.
If you are having surgery for a NET tumor, consider donating some of your tumor tissue to help research. The Neuroendocrine Tumor Research Foundation is
The Neuroendocrine Tumor Research Foundation (NETRF) has invested more than $1.5 million in advancing a precision form of radiation therapy for NETs called Peptide Receptor
Can an epigenetic enzyme under the right conditions contribute to the growth of cancer cells? If so, what happens if the enzyme is removed? Can
Request for Applications Issued The Neuroendocrine Tumor Research Foundation (NETRF) has announced its latest Request for Applications (RFA) and invites innovative research applications in neuroendocrine
NETRF announces the appointment of Susan Payson as Chief Development Officer. In this new position, Susan will work to expand NETRF’s base of support to